Epinastine intranasal - Inspire Pharmaceuticals
Latest Information Update: 24 Apr 2008
At a glance
- Originator Boehringer Ingelheim
- Developer Inspire Pharmaceuticals
- Class Antiallergics; Dibenzazepines; Eye disorder therapies; Imidazoles; Nonsedating antihistamines; Small molecules
- Mechanism of Action Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Seasonal allergic rhinitis
Most Recent Events
- 24 Apr 2008 Discontinued - Phase-III for Seasonal allergic rhinitis in USA (Intranasal)
- 18 Mar 2008 Pharmacokinetics data from a phase II trial in seasonal allergic rhinitis presented at the 64th Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI-2008)
- 29 Nov 2007 Phase-III clinical trials in Seasonal allergic rhinitis in USA (Intranasal)